Global Ophthalmology Drugs Market OutlookThe global ophthalmology drugs market is forecasted to expand at a CAGR of nearly 8% over the next several years, driven by the rising burden of vision ...

In diabetic macular edema, faricimab can improve visual acuity for treatment-naïve eyes or sustain vision for those ...

Anti-VEGF therapy for patients with retinopathy of prematurity reduces myopia compared with laser treatments, but comes with other risks.

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...

Abstract: Diabetic Retinopathy (DR) is a condition that is marked by deterioration of retinal blood vessels due to diabetes, serving as a primary factor for vision impairment. Diabetic Macular Edema ...

Explore the cost-effectiveness of ranibizumab biosimilars versus aflibercept in treating AMD and DME, revealing significant ...

Regeneron Pharmaceuticals, Inc. REGN announced a collaboration agreement with private company Tessera Therapeutics, Inc. for ...

Shares of Regeneron Pharmaceuticals REGN have gained 21.5% year to date compared with the industry’s growth of 10.2%. The ...

India’s soaring diabetes burden is fuelling a silent surge in diabetic retinopathy. Firstpost brings out a doctor’s ...

Kamuvudines are a new class of drugs that are derived from the anti-HIV nucleoside reverse transcriptase inhibitors. They are designed to inhibit the inflammasome, part of the innate immune system ...

Please provide your email address to receive an email when new articles are posted on . Lamivudine improved visual acuity in patients with center-involved diabetic macular edema. Researchers said the ...

While shares of Regeneron Pharmaceuticals are climbing this month, investors shouldn't find the stock too pricey, as it's valued at a reasonable 18 times trailing earnings. Regeneron is a compelling ...